awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q53268257-A77B72F8-5106-4726-84DF-70AE4553F717
Q53268257-A77B72F8-5106-4726-84DF-70AE4553F717
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53268257-A77B72F8-5106-4726-84DF-70AE4553F717
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
P2860
Q53268257-A77B72F8-5106-4726-84DF-70AE4553F717
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53268257-A77B72F8-5106-4726-84DF-70AE4553F717
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0d55aef6185abc12359de921e1e7c6936c6d5523
P2860
Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas.